Gensignia appoints CEO at US subsidiary

Lee McCracken joins the company from Pathwork Diagnostics

Gensignia, a London-based privately held microRNA company, has appointed Lee McCracken as Chief Executive of its subsidiary, Gensignia Life Sciences, Inc.

McCracken will lead the San Diego-based company with the aim of advancing Gensignia’s 'Dx/Rx' business model in oncology, with an initial focus on launching the company’s molecular diagnostic test for early detection of lung cancer.

McCracken has more than 20 years’ experience in the pharmaceutical, biotechnology, diagnostics and venture capital industries. He was recently President and CEO of Pathwork Diagnostics. Pathwork developed and commercialised an FDA-approved molecular diagnostic for cancer and was sold to Response Genetics in 2013.

Previously, McCracken held senior roles at Prometheus Laboratories, Diversa, GenStar Therapeutics, CombiChem and Allergan. He began his career in venture capital at Union Venture before joining 3i Capital.

You may also like

Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Manufacturing

Five critical design elements for Pelton wheel turbine flowmeters

Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Subscribe now